Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Patrick Schöffski, Robert G. Maki, Antoine Italiano, Hans Gelderblom, Giovanni Grignani, Veridiana Pires De Camargo, Sebastian Bauer, Sun Young Rha, Sant P. Chawla, Jean-Yves Blay, Peter Hohenberger, David R. D'Adamo, Benjamin Wang, Bartosz Chmielowski, Axel Le Cesne, George D. Demetri, Shreyaskumar Patel
Institutions: Universitair Ziekenhuis Leuven, Institut Bergonié, Leiden University Medical Center, Candiolo Cancer Institute, Hospital Sírio-Libanês, Severance Hospital, Sarcoma Oncology Center, Centre Léon Bérard, University of Mannheim, University Medical Centre Mannheim, Eisai (United States), University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Institut Gustave Roussy, Harvard University, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4242850173